NASDAQ: COEP AND Z SQUARED
- M Vanderbilt
- Sep 7
- 3 min read
Updated: Sep 13
Investment Alert
Invest in the Future of Digital Assets and Biotech Innovation
Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP) + Z Squared Merger | Q3 2025
A bold pivot. A strategic merger. A dual-industry powerhouse. Coeptis Therapeutics Holdings Inc. is on the verge of a game-changing transformation—merging with Z Squared Inc., a leading Dogecoin mining company, to create one of the largest publicly traded digital asset mining firms in the world. With the merger slated to close in Q3 2025, pending regulatory approvals, investors have a rare opportunity to get in early on a high-growth, diversified enterprise..
Experience the power of growth
Business Overview: From Cell Therapy to Crypto Mining
NASDAQ: COEP has long been a pioneer in oncology-focused cell therapy platforms, developing technologies like SNAP-CAR and GEAR-NK for cancer treatment. But with the upcoming merger, Coeptis will spin out its biopharma operations and rebrand as Z Squared Inc., shifting its core focus to digital asset mining—primarily Dogecoin (DOGE).
Key Highlights:
Coeptis will acquire 9,000 U.S.-based Dogecoin mining machines at closing
Z Squared becomes a wholly-owned subsidiary of Coeptis
Biopharma division to operate independently post-merger
New leadership team from Z Squared with deep expertise in digital assets
This strategic realignment positions Coeptis to capitalize on two high-growth sectors: biotech innovation and blockchain infrastructure.
Is it time to analyze your investments?
Market Analysis: Riding the Wave of Crypto Expansion
Dogecoin, once a meme, now commands a market cap exceeding $20 billion. Its proof-of-work (PoW) mechanism rewards miners with DOGE for validating transactions, creating a lucrative revenue stream for mining operations.
Why This Market Matters:
Growing adoption of DOGE for payments and smart contracts
Increasing institutional interest in crypto mining infrastructure
Regulatory clarity improving in key markets
With 9,000 mining machines and a focus on U.S.-based operations, Z Squared is poised to become a dominant force in the Dogecoin ecosystem
Competitive Analysis: A Unique Dual-Industry Advantage
While most crypto mining companies focus solely on digital assets, Coeptis offers a differentiated value proposition:
Feature | "COEP"/Z Squared | Traditional Crypto Miners | Biotech Firms |
Dogecoin Mining Scale | ✅ 9,000 machines | Limited exposure | ❌ None |
Nasdaq Listing | ✅ Yes | ✅ Some | ✅ Yes |
Biotech Legacy | ✅ Oncology platforms | ❌ None | ✅ Core focus |
Diversification | ✅ Dual-sector | ❌ Single-sector | ❌ Single-sector |
Financial Projections: Unlocking Multi-Billion Dollar Potential
While full post-merger financials are pending SEC filings, early indicators suggest strong upside:
Current COEP Market Cap: ~$27.7M
DOGE Mining Revenue Potential: Estimated $15M–$25M annually from 9,000 machines (based on current DOGE prices and mining yields)
Biotech IP Value: Coeptis retains rights to proprietary cell therapy platforms, which may be monetized or spun off
With crypto prices rebounding and biotech assets maturing, the combined entity offers asymmetric upside for early investors
Why Invest Now?
Ground-floor entry into a high-capacity Dogecoin mining operation
Exposure to biotech IP with potential licensing or acquisition upside
Nasdaq-listed liquidity and transparency
Experienced leadership from Group 10 Capital and Minting Dome Inc.
This isn’t just a pivot—it’s a launchpad. The merger of Coeptis and Z Squared is a rare convergence of innovation, infrastructure, and investor opportunity.
Price on the Move
References
Explore more at investors.coeptistx.com and join the future of biotech, AI, and digital assets.
DISCLAIMER
Vanderbiltreport.com is owned and operated by AB Holdings, a US-based corporation. We have received compensation of up to $100,000 regarding the profiling of Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP). ) starting on Sept 1, 2025. It is important to note that we do not own any shares in COEP: NASDAQ.
This page includes forward-looking statements subject to substantial risks and uncertainties. Actual outcomes may differ due to clinical trial results, regulatory decisions, financing needs, and execution. Investors should consult SEC filings before making decisions.
Comments